The secretome of colon cancer stem cells contains drug-metabolizing enzymes

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 84-96

  Emmink, Benjamin L ^a   Verheem, André ^a   Van Houdt, Winan J ^a   Steller, Ernst J A ^a   Govaert, Klaas M ^a   Pham, Thang V ^b   Piersma, Sander R ^b   Borel Rinkes, Inne H M ^a   Jimenez, Connie R ^b   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer stem cells; Colorectal cancer; Drug resistance; Mass spectrometry; Secretome

Indexed keywords

ACYLAMINO ACID RELEASING ENZYME; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BLEOMYCIN; BLEOMYCIN HYDROLASE; CHAPERONIN 60; CHAPERONIN CONTAINING TCP1; DESMOCOLLIN; DRUG METABOLIZING ENZYME; EPHRIN RECEPTOR B4; FERRITIN; FIBROBLAST GROWTH FACTOR 2; FUMARATE HYDRATASE; GLUTATHIONE PEROXIDASE 2; GLUTATHIONE SYNTHASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; IMMUNOGLOBULIN FC FRAGMENT; LEUKOTRIENE A4 HYDROLASE; MAFOSFAMIDE; MALATE DEHYDROGENASE (DECARBOXYLATING); NEUROLYSIN; PHOSPHOGLUCOMUTASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEASOME; PROTEIN DISULFIDE ISOMERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIBOSOME PROTEIN; SERINE ARGININE RICH PROTEIN; TRANSCRIPTION FACTOR NRF2; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CELL DEATH; CELL SURVIVAL; CELL TYPE; COLON CANCER; CONTROLLED STUDY; DIFFERENTIATED TUMOR CELL; DRUG DETOXIFICATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS;

CANCER STEM CELLS; COLORECTAL CANCER; DRUG RESISTANCE; MASS-SPECTROMETRY; SECRETOME;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLEOMYCIN; CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; COLONIC NEOPLASMS; COMPUTATIONAL BIOLOGY; CULTURE MEDIA, CONDITIONED; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PROTEIN FOLDING; PROTEOME; PROTEOMICS; RECURRENCE;

EID: 84881485624     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.06.027     Document Type: Article

References (48)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer Dec 15 2010, 127(12):2893-2917.
2. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Apr 20 2008, 26(12):2013-2019.
3. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med Jun 3 2004, 350(23):2335-2342.
4. Broadbridge V.T., Karapetis C.S., Price T.J. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther May 2012, 12(5):555-565.
5. Iqbal S., Lenz H.J. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol Sep 2004, 54(Suppl. 1):S32-S39.
6. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature Jan 4 2007, 445(7123):106-110.
7. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature Jan 4 2007, 445(7123):111-115.
8. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology Jun 2010, 138(6):2151-2162.
9. Vermeulen L., Todaro M., de Sousa M.F., Sprick M.R., Kemper K., Perez A.M., et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A Sep 9 2008, 105(36):13427-13432.
10. Pang R., Law W.L., Chu A.C., Poon J.T., Lam C.S., Chow A.K., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell Jun 4 2010, 6(6):603-615.
11. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell Oct 11 2007, 1(4):389-402.
12. Van Houdt W.J., Emmink B.L., Pham T.V., Piersma S.R., Verheem A., Vries R.G., et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics Dec 2011, 10(12):M111.
13. Cho R.W., Clarke M.F. Recent advances in cancer stem cells. Curr Opin Genet Dev Feb 2008, 18(1):48-53.
14. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3(6):e2428.
15. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A Aug 18 2009, 106(33):13820-13825.
16. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst May 7 2008, 100(9):672-679.
17. Emmink B.L., Van Houdt W.J., Vries R.G., Hoogwater F.J., Govaert K.M., Verheem A., et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology Jul 2011, 141(1):269-278.
18. Nagaria P., Robert C., Rassool F.V. DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. Biochim. Biophys. Acta. Feb 2013, 1830(2):2345-2353.
19. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature Apr 9 2009, 458(7239):780-783.
20. O'Brien C.A., Kreso A., Ryan P., Hermans K.G., Gibson L., Wang Y., et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell Jun 12 2012, 21(6):777-792.
21. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res Feb 1 2002, 62(3):910-916.
22. Yao L., Zhang Y., Chen K., Hu X., Xu L.X. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One 2011, 6(9):e24684.
23. Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res Dec 15 2001, 61(24):8851-8858.
24. Karagiannis G.S., Pavlou M.P., Diamandis E.P. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol Dec 2010, 4(6):496-510.
25. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem Mar 1 1996, 68(5):850-858.
26. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem Oct 15 2002, 74(20):5383-5392.
27. Pham T.V., Jimenez C.R. An accurate paired sample test for count data. Bioinformatics Sep 15 2012, 28(18):i596-i602.
28. Bendtsen J.D., Jensen L.J., Blom N., Von H.G., Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel Apr 2004, 17(4):349-356.
29. van der Flier L.G., Haegebarth A., Stange D.E., van de Wetering M., Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology Jul 2009, 137(1):15-17.
30. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell May 6 2011, 8(5):511-524.
31. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res Apr 15 2009, 69(8):3382-3389.
32. Bartkowiak K., Effenberger K.E., Harder S., Andreas A., Buck F., Peter-Katalinic J., et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res Jun 4 2010, 9(6):3158-3168.
33. Shenoy A., Butterworth E., Huang E.H. ALDH as a marker for enriching tumorigenic human colonic stem cells. Methods Mol Biol 2012, 916:373-385.
34. Emadi A., Jones R.J., Brodsky R.A. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol Nov 2009, 6(11):638-647.
35. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev Jun 2011, 7(2):292-306.
36. Zheng W., Johnston S.A., Joshua-Tor L. The unusual active site of Gal6/bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase. Cell Apr 3 1998, 93(1):103-109.
37. Li H.R., Shagisultanova E.I., Yamashita K., Piao Z., Perucho M., Malkhosyan S.R. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res Jul 15 2004, 64(14):4760-4767.
38. Chen J., Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer Feb 2005, 5(2):102-112.
39. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature Jan 29 2009, 457(7229):608-611.
40. Zhu L., Gibson P., Currle D.S., Tong Y., Richardson R.J., Bayazitov I.T., et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature Jan 29 2009, 457(7229):603-607.
41. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer Apr 2005, 5(4):275-284.
42. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis Jun 2008, 29(6):1235-1243.
43. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res Jul 1 2010, 70(13):5486-5496.
44. Zhang P., Singh A., Yegnasubramanian S., Esopi D., Kombairaju P., Bodas M., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther Feb 2010, 9(2):336-346.
45. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature Jul 7 2011, 475(7354):106-109.
46. Magesh S., Chen Y., Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev Jul 2012, 32(4):687-726.
47. Tichy E.D. Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells. Exp Biol Med (Maywood) Sep 1 2011, 236(9):987-996.
48. Sato T., van Es J.H., Snippert H.J., Stange D.E., Vries R.G., van den Born M., et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature Jan 20 2011, 469(7330):415-418.